Meta-analysis of increased heart rate and blood pressure associated with CNS stimulant treatment of ADHD in adults
Introduction
Attention-deficit/hyperactivity disorder (ADHD) is a common psychiatric disorder in children with worldwide prevalence estimates of approximately 3–10% (Akinbami et al., 2011, Polanczyk et al., 2007). Follow-up studies of children with this disorder have demonstrated that the symptoms of ADHD and its associated impairment persist into adulthood in approximately 30–50% of persons diagnosed with ADHD (Kessler et al., 2006, Faraone et al., 2006, Simon et al., 2009); it is estimated that 4–5% of American adults have this disorder. As the recognition that ADHD may persist into adulthood has gained greater acceptance, there has been a coincident increase in the use of CNS stimulants in adults with ADHD. For example, nearly 2% of American adults 20–44 years old were using stimulant medications for ADHD in 2010 representing marked increases in use among men (+188%) and women (+265%) over the prior decade (Medco, 2011). Faraone and Glatt (2009) conducted a meta-analysis of aADHD pharmacotherapy and concluded that both short- and long-acting CNS stimulants were effective (effect sizes of 0.96 and 0.73, respectively) in treating the over-activity, impulsivity, and inattention characteristic of patients with ADHD.
Despite their increasing use and documented efficacy, CNS stimulant pharmacotherapy has remained controversial due to safety concerns, including the potential for abuse and adverse cardiovascular side effects. In children, a case-control study suggested that stimulant exposure was associated with a 7-fold increased risk of sudden unexplained death as 1.8% of children with sudden unexplained death compared with 0.4% of children dying in a car accident had been exposed to methylphenidate (Gould et al., 2009). Subsequent studies of large claims databases failed to identify an increased risk for serious cardiovascular events associated with the use of CNS stimulants and concluded that the absolute and relative risks associated with these medications are exceedingly small in children (Winterstein et al., 2007, Mccarthy et al., 2009, Schelleman et al., 2011, Cooper et al., 2011).
Estimates of cardiovascular safety of CNS stimulants in children cannot be directly generalized to adults with ADHD, however. In general, adults have accumulated more cardiovascular disease risk factors with subsequently higher incidence rates in each decade of life. It is also noteworthy that adults with ADHD are at an even greater risk for developing unhealthy lifestyle practices and cardiovascular risk factors, such as obesity, early initiation of tobacco use, and a greater probability of chronic substance misuse (Franke et al., 2011, De Zwaan et al., 2011, Wilens et al., 2011, Matthies et al., 2012). Therefore, pharmacotherapy for aADHD results in exposure to CNS stimulants during a period of greater risk of cardiovascular disease.
The goal of this report is to critically review the available literature relevant to the cardiovascular safety of stimulants for aADHD. In this summary overview, we update previous literature reviews and conduct a formal meta-analysis of the effects of CNS stimulants in adults on several pathophysiologic cardiovascular parameters based on data from placebo-controlled trials conducted in adults with ADHD.
Section snippets
Literature search
Since there have been recent reviews of cardiovascular safety (Hammerness et al., 2011) and meta-analyses of clinical response (Faraone and Glatt, 2009) of the aADHD treatment literature, we conducted a systematic search of literature published since 2010 through PubMed using the search terms ADHD, adult, clinical trial, and stimulant. We extracted the following information from each article: (1) drug name and dose; (2) baseline, endpoint and change values for systolic blood pressure (SBP),
Statistical analysis
We extracted and analyzed the change from baseline values at the time of trial entry in cardiovascular parameters in adults with ADHD randomized to treatment with either an active CNS stimulant or to placebo. We used random-effects meta-analysis to estimate change in these variables pooled within the active and placebo groups and used random-effects meta-analytic regression models to estimate the magnitude and statistical significance of the change scores in the active relative to placebo
Results
The ten randomized, placebo-controlled clinical trials of CNS stimulants for aADHD included in this meta-analysis are listed in Table 1. All studies meeting our inclusion criteria were published after 2005 and focused predominantly on preparations designed to provide day-long coverage with a single dose. The one exception was a study of immediate release methylphenidate (Spencer et al., 2005) that required three daily doses and effectively provided the same coverage as a long-acting preparation
Discussion
In this meta-analysis of published clinical trials, we provide a contemporary estimate of change in blood pressure and pulse findings associated with CNS stimulant use for aADHD. In 2665 patients from 10 trials, we observed that use of CNS stimulants was associated with an increase in heart rate of approximately 5 bpm and an increase in systolic or diastolic blood pressure of 1.2 mmHg. We also noted a low overall risk (≤5%) of clinically significant cardiovascular events, including tachycardia or
Role of the funding source
The authors were supported by the following NIH Grants R01HL035434 (Goldberg, Mick), R01HL105268 (Goldberg, McManus), R01HL69874 (Goldberg, McManus), and P30HD004147 (Mick). The individual NIH institutions represented had no further role in study design; in the collection, analysis or interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.
Contributors
All authors have contributed to and have approved the final manuscript. Dr. Mick designed this study, preformed the literature review and conducted all meta-analyses. Dr. Mick generated the first draft which was edited by Drs. McManus and Goldberg who provided further interpretation of these results.
Conflict of interest
All authors declare that they have no conflicts of interest.
Acknowledgment
None.
References (49)
- et al.
A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder
Biol. Psychiatry
(2006) - et al.
Elevated resting heart rate is an independent risk factor for cardiovascular disease in healthy men and women
Am. Heart J.
(2010) - et al.
Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial
Lancet
(2008) - et al.
Prognostic value of home heart rate for cardiovascular mortality in the general population: the Ohasama study
Am. J. Hypertens.
(2004) - et al.
A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder
Biol. Psychiatry
(2008) - et al.
Heart rate as a risk factor for cardiovascular disease
Prog. Cardiovasc. Dis.
(2009) - et al.
A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder
Biol. Psychiatry
(2005) - et al.
Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder
Biol. Psychiatry
(2007) - et al.
Does ADHD predict substance-use disorders? A 10-year follow-up study of young adults with ADHD
J. Am. Acad. Child Adolesc. Psychiatry
(2011) - et al.
Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder
J. Clin. Psychiatry
(2008)
Short-term effects of lisdexamfetamine dimesylate on cardiovascular parameters in a 4-week clinical trial in adults with attention-deficit/hyperactivity disorder
J. Clin. Psychiatry
Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study
J. Clin. Psychopharmacol.
Attention deficit hyperactivity disorder among children aged 5–17 years in the United States, 1998–2009
NCHS Data Brief
The effects of lisdexamfetamine dimesylate on the driving performance of young adults with ADHD: a randomized, double-blind, placebo-controlled study using a validated driving simulator paradigm
J. Psychiatr. Res
A randomized, 3-phase, 34-week, double-blind, long-term efficacy study of osmotic-release oral system-methylphenidate in adults with attention-deficit/hyperactivity disorder
J. Clin. Psychopharmacol.
Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder
BMC Psychiatry
Efficacy and safety of prolonged-release OROS methylphenidate in adults with attention deficit/hyperactivity disorder: a 13-week, randomized, double-blind, placebo-controlled, fixed-dose study
World J. Biol. Psychiatry
ADHD drugs and serious cardiovascular events in children and young adults
N. Engl. J. Med.
Association between obesity and adult attention-deficit/hyperactivity disorder in a German community-based sample
Obes. Facts
Modeled economic evaluation of alternative strategies to reduce sudden cardiac death among children treated for attention deficit/hyperactivity disorder
Circulation
The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies
Psychol. Med.
A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes
J. Clin. Psychiatry
The genetics of attention deficit/hyperactivity disorder in adults, a review
Mol. Psychiatry
Pre-existing cardiovascular conditions and pharmacological treatment of adult ADHD
Pharmacoepidemiol. Drug Saf.
Cited by (92)
Examining the relationship between resting heart rate and callous-unemotional traits in juvenile delinquency
2023, Journal of Criminal JusticeIs there a place for dietetic interventions in adult ADHD?
2022, Progress in Neuro-Psychopharmacology and Biological PsychiatryCitation Excerpt :After two years, only half of those who started a medication will still be using it, and after five years that number drops to around one-third (Charach et al., 2004). Furthermore, psychostimulants use is accompanied by the risk of side effects, including increased heart rate and blood pressure (Hennissen et al., 2017; Liang et al., 2018; Mick et al., 2013). Psychotherapies, especially parent-training (Rimestad et al., 2019) and cognitive-behavioral therapies (Young et al., 2020), can also help individuals with ADHD.
Updates in Pharmacologic Strategies in Adult Attention-Deficit/Hyperactivity Disorder
2022, Child and Adolescent Psychiatric Clinics of North AmericaMethylphenidate and Short-Term Cardiovascular Risk
2024, JAMA Network OpenCardiovascular Safety of Amphetamine/Dextroamphetamine versus Methylphenidate in Older Adults
2024, Journal of Pharmacy Practice